A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

NCT ID: NCT06782555

Last Updated: 2025-01-21

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 71 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-08
• Study Completion Date: 2028-01-31

Brief Summary

The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).

Detailed Description

Tumor hypoxia can lead to poor effector T-cell penetration and immunosuppressive signaling via myeloid-derived suppressor cells, myofibroblasts, and regulatory T-cells. Disruption of these hypoxic regions within the tumor microenvironment by the hypoxia-directed cytotoxic agent evofosfamide may enhance the ability of immune checkpoint inhibitors to reject otherwise resistant solid tumors. The hypothesis tested in this study is that evofosfamide, by specifically targeting the hypoxic tumor microenvironment, may enhance the anti-tumor effects of the immune checkpoint inhibitors zalifrelimab (anti-CTLA-4) and balstilimab (anti-PD-1) in select tumors that are generally resistant to therapy.

In the Phase 1 dose escalation part of the study, the maximum tolerated dose (or maximum allowable dose) of evofosfamide in combination with zalifrelimab and balstilimab will be determined. A recommended Phase 2 dose (RP2D) will be determined based on safety and the totality of data.

The Phase 2 dose expansion part of the study will evaluate the Phase 2 dose of the triplet combination in 3 cohorts: 1) patients with locally advanced or metastatic castration-resistant prostate cancer; 2) patients with locally advanced or metastatic pancreatic cancer; and 3) patients with locally advanced or metastatic HPV-negative SCCHN. Each cohort expansion will be carried out independently.

Conditions

Metastatic Prostate Cancer; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Pancreatic Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Castration-resistant prostate cancer

Evofosfamide + zalifrelimab + balstilimab

Group Type: EXPERIMENTAL

Evofosfamide

Intervention Type: DRUG

Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.

Zalifrelimab

Intervention Type: DRUG

Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.

Balstilimab

Intervention Type: DRUG

Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.

Pancreatic cancer

Evofosfamide + zalifrelimab + balstilimab

Group Type: EXPERIMENTAL

Evofosfamide

Intervention Type: DRUG

Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.

Zalifrelimab

Intervention Type: DRUG

Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.

Balstilimab

Intervention Type: DRUG

Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.

Human papilloma virus-negative squamous cell carcinoma of the head and neck

Evofosfamide + zalifrelimab + balstilimab

Group Type: EXPERIMENTAL

Evofosfamide

Intervention Type: DRUG

Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.

Zalifrelimab

Intervention Type: DRUG

Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.

Balstilimab

Intervention Type: DRUG

Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.

Interventions

Evofosfamide

Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.

Intervention Type: DRUG

Zalifrelimab

Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.

Intervention Type: DRUG

Balstilimab

Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Histologically confirmed locally advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, or HPV-negative SCCHN for which no other lines of standard therapy with demonstrated clinical benefit are available or appropriate as treatment.

2. Appropriate to enter a clinical trial with a minimum estimated life expectancy of at least 3 months.

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

4. Measurable disease as defined by RECIST 1.1. Patients with castration-resistant prostate cancer can have measurable or evaluable disease per PCWG3 criteria. Patients with evaluable disease must have documented evidence of PD as defined by any of the following:

• PSA progression: minimum of 2 rising values (3 measurements) obtained a minimum of 7 days apart with the last result being at least ≥4.0 ng/mL.
• New or increasing non-bone disease per RECIST 1.1 criteria.
• Positive bone scan with 2 or more new lesions (PCWG3).

5. Adequate bone marrow function as defined by the following laboratory test results obtained within 7 days of Cycle 1 Day 1:

• White blood cell count ≥2500 cells/mm3.
• Absolute neutrophil count ≥1500 cells/mm3.
• Absolute lymphocyte count >500 cells/mm3.
• Hemoglobin ≥9 g/dL.
• Platelets ≥75,000 cells/mm3.

6. Adequate liver function as defined by the following laboratory test results obtained within 7 days of Cycle 1 Day 1:

• Bilirubin ≤1.5 × institutional ULN; for patients with known Gilbert's syndrome, ≤3 × institutional ULN.
• Aspartate aminotransferase (SGOT) and alanine aminotransferase (SGPT) ≤3 × institutional ULN; if liver metastases are present, then ≤5 × ULN is allowed.

7. At least 3 weeks from previous cytotoxic chemotherapy or radiation therapy and at least 5 half-lives or 6 weeks, whichever is shorter, from targeted or biologic therapy with the exception of CTLA-4, PD-1, or PD-L1 blocking antibodies for which only a 2 week interval is required. Patients with prostate cancer, unless they have undergone prior orchiectomy, may continue to receive androgen deprivation therapy, anti-androgen therapy, or therapy that interferes with androgenic stimulation.

8. All patients must be willing to undergo a biopsy to provide a new tumor sample within 14 days of Cycle 1 Day 1. Patients who are unable to undergo a biopsy at screening must submit archival tumor tissue retrieved within the last 6 calendar months. Patients must also consent to undergo a biopsy between Day 15 of Cycle 2 and Day 8 of Cycle 3 in those subjects which it is clinically safe and attainable. A biopsy is not required for participants with metastatic prostate cancer with bone-only disease or inaccessible soft tissue lesions.

9. Calculated creatinine clearance ≥ 60 mL/min (by the Cockcroft Gault formula) within 7 days of Cycle 1 Day 1

Exclusion Criteria

1. A history of currently active/uncontrolled autoimmune diseases or disorders, including inflammatory bowel disease (including Crohn's disease and ulcerative colitis), rheumatoid arthritis, systemic sclerosis (scleroderma), systemic lupus erythematosus, or autoimmune vasculitis (eg, Wegener's granulomatosis).

2. Patients with prior history of any Grade 3 or Grade 4 AEs from anti-CTLA-4, anti-PD-1/PD-L1, or anti-CTLA-4 and anti-PD-1/PD-L-1 combination therapy.

3. History of acute diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, abdominal carcinomatosis, or other known risk factors for bowel perforation.

4. Patients on long-term systemic steroids (>10 mg daily prednisone equivalent initiated >2 weeks prior to study enrollment). Inhaled or topical steroids are permitted in the absence of active autoimmune disease.

5. Any underlying medical or psychiatric condition, which in the opinion of the investigator, will make the administration of study treatment hazardous or obscure the interpretation of AEs, e.g., a condition associated with frequent diarrhea or chronic skin conditions, recent surgery (within 30 days) or colonic biopsy from which the patient has not recovered, partial endocrine organ deficiencies, or substance abuse.

6. Concomitant use of QT-prolonging drugs with a risk of causing Torsades de Pointes (TdP).

7. History of risk factors for TdP, including family history of long QT syndrome.

8. Corrected QT (QTc) interval of ≥470 msec calculated according to Fridericia's formula (QTc=QT/RR [0.33]).

9. Sustained systolic blood pressure (BP) >140 mmHg or <90 mmHg and sustained diastolic BP >100 mmHg or <60 mmHg.

10. Patients with newly diagnosed, uncontrolled and/or untreated cancer-related central nervous system disease. Patients with treated brain metastases that are radiographically or clinically stable for at least 2 weeks after therapy and have no evidence of cavitation or hemorrhage in the brain lesion(s) are eligible if they are asymptomatic and do not require corticosteroids (must have discontinued steroids at least 1 week prior to study enrollment).

11. Uncontrolled intercurrent illness including, but not limited to, myocardial infarction within 6 months, unstable symptomatic ischemic heart disease, significant cardiac arrythmias, active uncontrolled infection requiring systemic therapy, or psychiatric illness/social situations that would limit compliance with study requirements.

12. Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to study enrollment.

13. Current evidence of active and uncontrolled infection, New York Heart Association Class III-IV chronic heart failure, documented Child's class B and C cirrhosis, active symptomatic pancreatitis, or uncontrolled medical disease which, in the opinion of the investigator, could compromise assessment of study treatment efficacy.

14. Active human immunodeficiency virus infection (Exception: patients with well-controlled HIV [e.g., CD4 ≥ 350 cells/uL and undetectable viral load] who have been on an effective (drug, dosage, and schedule associated with reduction and control of the viral load) antiretroviral therapy (ART) for ≥ 4 weeks are eligible). Patients with a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the last 12 months are not eligible. Note: Drug-drug interactions with ART occur via many mechanisms, with cytochrome P450 CYP3A4-mediated interactions being the most common. Patients who are using concurrent strong or moderate CYP3A4 inhibitors (e.g., ritonavir, cobicistat) or strong or moderate CYP3A4 inducers must be switched to an alternate effective ART regimen ≥ 4 weeks before study enrollment or should be excluded from the study if their regimen cannot be altered.

15. Active or chronic hepatitis B or C virus infection. Patients with a history of HCV infection must have completed curative antiviral treatment and must have a viral load below the limit of quantification. A patient who is HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution is eligible.

16. Known hypersensitivity to any components of the study treatment or any of their excipients or analogs or drugs of similar chemical or biologic composition.

17. Live vaccine within 4 weeks prior to study enrollment.

18. Concomitant therapy with interleukin-2, interferon, or other non-study immunotherapy agents, or immunosuppressive agents.

19. Concomitant use of strong or moderate inhibitors or strong or moderate inducers of CYP3A4 within 14 days or 5 half-lives (whichever is longer) prior to study enrollment and for the duration of study treatment.

20. Concomitant use of anti-cancer chemotherapy, radiotherapy, hormone therapy, or targeted therapy. Patients with prostate cancer may continue treatment with anti-androgen and bone targeted therapies (e.g., zoledronic acid and denosumab). Palliative radiotherapy to nontarget lesions is permitted.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Agenus Inc.

INDUSTRY

Sponsor Role: collaborator

ImmunoGenesis

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

MD Anderson Cancer Center

Houston, Texas, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Charles Schweizer, PhD

Role: CONTACT

charles.schweizer@immunogenesis.com

346-772-0336

Facility Contacts

LiYing Jiang, CCRP

Role: primary

ljiang1@mdanderson.org

713-792-9191

David S. Hong, PhD

Role: backup

Other Identifiers

EVO-011

Identifier Type: -

Identifier Source: org_study_id